Arcus Biosciences, Inc. (RCUS)

Market Cap	1.77B
Revenue (ttm)	262.00M
Net Income (ttm)	-298.00M
Shares Out	106.43M
EPS (ttm)	-3.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,873,518
Open	15.82
Previous Close	14.60
Day's Range	15.09 - 17.17
52-Week Range	6.50 - 18.98
Beta	0.77
Analysts	Buy
Price Target	26.00 (+56.53%)
Earnings Date	Nov 5, 2025

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 15, 2018
• Employees: 627
• Stock Exchange: NYSE
• Ticker Symbol: RCUS
• Website: https://www.arcusbio.com

Financial Performance

In 2024, Arcus Biosciences's revenue was $258.00 million, an increase of 120.51% compared to the previous year's $117.00 million. Losses were -$283.00 million, -7.82% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price target is $26.0, which is an increase of 56.53% from the latest price.

Price Target

$26.0

(56.53% upside)

Analyst Consensus: Buy